臨床整形外科59巻4号

2024年04月発行

特集 脊椎関節炎SpAを理解する—疾患概念・診断基準・最新治療

炎症性腸疾患に伴う脊椎関節炎

著者： 冨田哲也¹

所属機関： ¹森ノ宮医療大学大学院保健医療学研究科

ページ範囲：P.391 - P.395

脊椎関節炎(SpA)は関節外症状として腸炎症を合併することが知られている．また炎症性腸疾患(IBD)の腸管外症状として関節炎が合併することは以前から知られている事実である．近年IBDとSpAの共通の病態として，IL-23/IL-17 pathwayが注目されている．末梢性関節炎や体軸性関節炎が合併するが，その実態や治療方針は明確ではなく臨床現場では手探りな状況である．積極的な骨・関節専門医と消化器専門医による横断的診療連携によるエビデンスの構築が重要である．

参考文献

1) Bargen JA. Complications and sequelae of chronic ulcerative colitis. Ann Intern Med 1929;3(4):335-52.

2) Kamo K, Shuto T, Haraguchi A. Prevalence of spondyloarthritis symptom in inflammatory bowel disease patients:a questionnaire survey. Mod Rheumatol 2015;25(3):435-7.

3) 3 炎症性腸疾患に伴う脊椎関節炎．日本脊椎関節炎学会，厚生労働科学研究費補助金(難治性疾患政策研究事業)「強直性脊椎炎に代表される脊椎関節炎の疫学調査・診断基準作成と診療ガイドライン策定を目指した大規模多施設研究」班(編)．脊椎関節炎診療の手引き2020．東京：診断と治療社；2020．p.104-7．

4) 猿田雅之，冨田哲也．炎症性腸疾患に伴う脊椎関節炎(Inflammatory bowel disease related spondyloarthritis)の本邦における実態調査．冨田哲也．厚生労働科学研究費補助金難治性疾患等政策研究事業．強直性脊椎炎に代表される脊椎関節炎の疫学調査・診断基準作成と診療ガイドライン策定を目指した大規模多施設研究 平成30年度総括・分担研究報告書．2019．

5) Ossum AM, Palm Ø, Cvancarova M, et al;IBSEN Study Group. The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD patients:results from a population-based inception cohort (20-year follow-up in the ibsen study). Inflamm Bowel Dis 2020;26(1):114-24.

6) Karreman MC, Luime JJ, Hazes JMW, et al. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease:a systematic review and meta-analysis. J Crohns Colitis 2017;11(5):631-42.

7) Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009;15(20):2449-55.

8) Østgård RD, Deleuran BW, Dam MY, et al. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol 2018;47(1):48-55.

9) Fauny M, D'Amico F, Bonovas S, et al. Faecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases:a systematic review. J Crohns Colitis 2020;14(5):688-93.

10) Klingberg E, Carlsten H, Hilme E, et al. Calprotectin in ankylosing spondylitis--frequently elevated in feces, but normal in serum. Scand J Gastroenterol 2012;47(4):435-44.

11) Zioga N, Kogias D, Lampropoulou V, et al. Inflammatory bowel disease-related spondyloarthritis:the last unexplored territory of rheumatology. Mediterr J Rheumatol 2022;33(Suppl 1):126-36.

12) El Miedany Y, Youssef S, Ahmed I, et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;101(2):311-7.

13) Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission:a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006;4(2):203-11.

14) Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91.

15) Prajapati DN, Knox JF, Emmons J, et al. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 2003;37(2):125-8.

16) Holtmann MH, Gerts AL, Weinman A, et al. Treatment of Crohn's disease with leflunomide as second-line immunosuppression:a phase 1 open-label trial on efficacy, tolerability and safety. Dig Dis Sci 2008;53(4):1025-32.

17) Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn's disease:an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004;63(12):1664-9.

18) Conigliaro P, Chimenti MS, Triggianese P, et al. Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease:a STROBE-compliant study. Medicine (Baltimore) 2021;100(12):e25122. doi:10.1097/MD.0000000000025122.

19) Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62(1):74-6.

20) Luchetti MM, Benfaremo D, Ciccia F, et al. Adalimumab efficacy in enteropathic spondyloarthritis:a 12-mo observational multidisciplinary study. World J Gastroenterol 2017;23(39):7139-49.

21) Pugliese D, Daperno M, Fiorino G, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis:an IG-IBD study. Dig Liver Dis 2019;51(7):972-7.

22) Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 2019;71(2):258-70.

23) Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis:data from 21 clinical trials. Rheumatology (Oxford) 2020;59(12):3834-44.